CS
RETA
Candriam SCA’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,377
| Closed | -$450K | – | 894 |
|
|
2023
Q1 | $450K | Buy |
+5,377
| New | +$450K | ﹤0.01% | 789 |
|
|
2021
Q2 | – | Sell |
-151,707
| Closed | -$18M | – | 945 |
|
|
2021
Q1 | $18M | Hold |
151,707
| – | – | 0.15% | 151 |
|
|
2020
Q4 | $18.8M | Sell |
151,707
-4,877
| -3% | -$603K | 0.15% | 152 |
|
|
2020
Q3 | $15.3M | Hold |
156,584
| – | – | 0.14% | 165 |
|
|
2020
Q2 | $24.4M | Buy |
156,584
+41,184
| +36% | +$6.43M | 0.26% | 101 |
|
|
2020
Q1 | $23.1M | Hold |
115,400
| – | – | 0.26% | 80 |
|
|
2019
Q4 | $23.6M | Sell |
115,400
-80,800
| -41% | -$16.5M | 0.25% | 80 |
|
|
2019
Q3 | $15.8M | Sell |
196,200
-53,000
| -21% | -$4.26M | 0.21% | 110 |
|
|
2019
Q2 | $23.4M | Hold |
249,200
| – | – | 0.29% | 74 |
|
|
2019
Q1 | $21.3M | Buy |
249,200
+50,000
| +25% | +$4.27M | 0.27% | 83 |
|
|
2018
Q4 | $11.2M | Buy |
199,200
+4,000
| +2% | +$224K | 0.17% | 137 |
|
|
2018
Q3 | $16M | Buy |
195,200
+48,500
| +33% | +$3.97M | 0.21% | 112 |
|
|
2018
Q2 | $5.13M | Buy |
146,700
+54,700
| +59% | +$1.91M | 0.08% | 294 |
|
|
2018
Q1 | $1.89M | Hold |
92,000
| – | – | 0.03% | 492 |
|
|
2017
Q4 | $2.61M | Buy |
92,000
+32,000
| +53% | +$906K | 0.05% | 402 |
|
|
2017
Q3 | $1.87M | Buy |
+60,000
| New | +$1.87M | 0.03% | 468 |
|